RecruitingPhase 2NCT05862168
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
Studying Squamous cell carcinoma of the oral tongue
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Weijia Fang, MD
- Intervention
- Tislelizumab(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2028
Study locations (1)
- First affiliated hospital, School of Medicine, Zhejiang University, Hangzhou, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05862168 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the oral tongue
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07402525Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled TrialSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGNCT07343271Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and OropharynxUniversity Hospital, Strasbourg, France
- RECRUITINGNCT06055868People Living With HIV, Oral and Oropharyngeal Cancer, and Health EquityUniversity of California, San Francisco
- RECRUITINGPHASE2, PHASE3NCT05893888Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell CarcinomaPrivo Technologies
- RECRUITINGPHASE2NCT06485778A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell CarcinomaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT06321003SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence TomographyUniversity of Palermo
- RECRUITINGPHASE3NCT05798793Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell CarcinomaHospital of Stomatology, Wuhan University
- ACTIVE NOT RECRUITINGPHASE2NCT06009861Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)Peking University Hospital of Stomatology
See all trials for Squamous cell carcinoma of the oral tongue →